

ATTENTION

PURCHASERS OF THE DRUGS LORAZEPAM AND/OR CLORAZEPATE

If you are a US resident who purchased the generic drugs Lorazepam and/or Clorazepate from January 1, 1998 through December 31, 1999,

Please Read This Notice Carefully.

The Attorneys General of the fifty States, the District of Columbia (“Plaintiff States”), and the Federal Trade Commission, have brought lawsuits against Mylan Laboratories, Inc., Cambrex Corporation, Profarmaco S.r.l., Gyma Laboratories of America, Inc., and SST Corporation (collectively, “Defendants”) claiming that as a result of Defendants’ conduct, consumers were overcharged for the purchase of Lorazepam and/or Clorazepate. Defendants have denied any wrongdoing or liability. The Plaintiffs and Defendants have agreed to a proposed settlement (“Proposed Settlement”) of these claims.

Under the Proposed Settlement, the sum of \$100,500,000 will be paid to Plaintiff States to be used to reimburse consumers and state agencies some portion of any overcharge they may have incurred from purchasing either or both drugs.

The Court will hold a final approval hearing on the Proposed Settlement on November 29, 2001 in the Courtroom of the Honorable Thomas Hogan, at the U.S. District Court, District of Columbia, 333 Constitution Ave., NW, Washington, D.C. 20001.

Your Rights

- If you purchased Lorazepam and/or Clorazepate from January 1, 1998

through December 31, 1999 (“Relevant Period”), you are a member of the Settlement Group. If you wish to remain a member of the Settlement Group, you will be bound by all orders of the Court. Any legal claims you may have against the Defendants relating to the conduct alleged in this action will be resolved and forever released, and you will be bound by the consumer claims process described herein.

- If you remain a member of the Settlement Group and you wish to be reimbursed for some portion of the overcharge you may have incurred when you purchased the drugs during the Relevant Period, you must submit a claim for reimbursement, postmarked by September 29, 2001, to the Lorazepam/Clorazepate Settlement Administrator at the address identified below.

- If you do not wish to remain a member of the Settlement Group, you must mail a written opt-out request, postmarked by August 31, 2001, to the Clerk of the Court and the Lorazepam/Clorazepate Settlement Administrator.

- As a member of the Settlement Group, you may object to the Proposed Settlement, enter an appearance in this matter through counsel, or appear at the final approval hearing.

For Complete Information, a Copy of the Notice of Proposed Settlement, and a Claim Form,

Call: **1-800-899-5806**

Or Write: **Lorazepam/Clorazepate Settlement Administrator
P.O. Box 1605, Faribault, MN 55021-1605**

Or Access: **www.agsettlement.com**

Clerk of the Court, U.S. District Court, District of Columbia

PLEASE DO NOT CONTACT THE COURT